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a b s t r a c t
The epithelial to mesenchymal transition (EMT) is characterized by a loss of cell polarity, a decrease in the
epithelial cell marker E-cadherin, and an increase in mesenchymal markers including the zinc-ﬁnger E-box binding homeobox (ZEB1). The EMT is also associated with an increase in cell migration and anchorage-independent
growth. Induction of a reversal of the EMT, a mesenchymal to epithelial transition (MET), is an emerging strategy
being explored to attenuate the metastatic potential of aggressive cancer types, such as triple-negative breast cancers (TNBCs) and tamoxifen-resistant (TAMR) ER-positive breast cancers, which have a mesenchymal phenotype.
Patients with these aggressive cancers have poor prognoses, quick relapse, and resistance to most chemotherapeutic drugs. Overexpression of extracellular signal-regulated kinase (ERK) 1/2 and ERK5 is associated with
poor patient survival in breast cancer. Moreover, TNBC and tamoxifen resistant cancers are unresponsive to most
targeted clinical therapies and there is a dire need for alternative therapies.
In the current study, we found that MAPK3, MAPK1, and MAPK7 gene expression correlated with EMT markers and poor overall survival in breast cancer patients using publicly available datasets. The eﬀect of ERK1/2
and ERK5 pathway inhibition on MET was evaluated in MDA-MB-231, BT-549 TNBC cells, and tamoxifenresistant MCF-7 breast cancer cells. Moreover, TU-BcX-4IC patient-derived primary TNBC cells were included
to enhance the translational relevance of our study. We evaluated the eﬀect of pharmacological inhibitors and
lentivirus-induced activation or inhibition of the MEK1/2-ERK1/2 and MEK5-ERK5 pathways on cell morphology,
E-cadherin, vimentin and ZEB1 expression. Additionally, the eﬀects of pharmacological inhibition of trametinib
and XMD8-92 on nuclear localization of ERK1/2 and ERK5, cell migration, proliferation, and spheroid formation
were evaluated. Novel compounds that target the MEK1/2 and MEK5 pathways were used in combination with
the AKT inhibitor ipatasertib to understand cell-speciﬁc responses to kinase inhibition. The results from this study
will aid in the design of innovative therapeutic strategies that target cancer metastases.

Abbreviations: E-cadherin, epithelial cadherin; ERK, extracellular signal-regulated kinase; EMT, epithelial to mesenchymal transition; GFP, green ﬂuorescent
protein; MEK, mitogen-activated protein kinase kinase; MET, mesenchymal to epithelial transition; PDX, Patient-derived xenograft; RSK, ribosomal s6 kinase; TAMR,
tamoxifen-resistant; TNBC, triple-negative breast cancer; ZEB, zinc-ﬁnger E-box binding homeobox.
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1. Introduction

2.2. Inhibitor treatment and EGF stimulation

Metastases account for ~90% human deaths due to cancer [1].
The epithelial to mesenchymal transition (EMT), one of the ﬁrst steps
in metastases, leads to the loss of cell polarity, downregulation of Ecadherin, and upregulation of mesenchymal markers snail, zinc-ﬁnger
E-box binding homeobox (ZEB1), and vimentin. EMT is also associated
with drug resistance [2]. Additionally, cytoskeletal reorganization and
loss of E-cadherin is an important step to initiate the epithelial to mesenchymal transition (EMT) and metastases [3-5]. Reversing the mesenchymal phenotype of cancer cells through activation of the mesenchymal to epithelial transition (MET) program is an emerging approach to
attenuate the metastatic properties of cancer cells.
Most triple-negative breast cancer (TNBC) cells have a mesenchymal
phenotype and show poor sensitivity to chemotherapy agents [6]. The
loss of estrogen, progesterone hormone receptors, and human epidermal growth factor receptors (HER2) contributes to the aggressive state
of TNBC and lack of targeted therapies [7]. Tamoxifen-resistance is associated with an induction of EMT in estrogen receptor (ER) positive
MCF-7 cells [8–10]. An increasing body of evidence suggests that activation of ERK1/2 and ERK5 signaling is a marker for node metastases
and a predictor of poor responses to hormone therapy such as 4-OHT
[11–13]. Activation of intracellular signaling pathways, such as the ERK
MAPK pathways, mediates tumorigenesis in TNBCs and tamoxifen resistant breast cancers [14,15]. ERK1/2 activation is known to mediate
EMT in several cancer models [16–19]. Moreover, overexpression of the
newest member of the MAPK family, ERK5, induces EMT and hormoneindependent growth of breast cancer [13].
To identify the link between MAPK pathways and EMT, MAPK3
(ERK1), MAPK1(ERK2), and MAPK7 (ERK5) gene expression was correlated with EMT markers CDH1, ZEB1, or VIM in tumors derived
from TNBC patients using publicly available datasets. Moreover, overall survival in patients with inﬂammatory breast cancer was plotted
against ERK1, ERK2, or ERK5 gene expression using publicly available
datasets. Although activation of the ERK1/2 and ERK5 pathways have
been shown to mediate EMT, the eﬀect of ERK1/2 and ERK5 inhibition
on MET is poorly understood in cancer.
We hypothesize that inhibition of the ERK1/2 and ERK5 pathways
is a relevant strategy to induce a MET in TNBCs. To test this hypothesis, we examined the eﬀects the ERK1/2 and ERK5 pathways on the
MET and nuclear localization of ERK5 using the pharmacological inhibitors trametinib (MEK1/2 inhibitor) and XMD8-92 (ERK5 inhibitor).
Moreover, the eﬀect of lentivirus-mediated activation or inhibition of
ERK1/2 and ERK5 pathway components on the MET was examined.
Cell morphology and protein expression of epithelial and mesenchymal
markers, E-cadherin and ZEB1, respectively, were examined. Activation
of ERK1/2, ERK5, and RSK, a downstream target of MAPK signaling,
was evaluated. The eﬀect of XMD8-92 and trametinib was evaluated on
cell migration and cell proliferation in TNBC and TAMR breast cancer.
Moreover, the crosstalk between MEK-ERK and PI3K-AKT pathway with
respect to EMT was studied in a spheroid viability assay.

Cells were cultured in a 6-well plate (250,000 cells/well) for 24 hrs.
To examine kinase activity or inhibition, the cells were serum-starved
for 18-24 h. The inhibitors XMD8-92 (Tocris, Minneapolis, MN) and
trametinib (Selleckchem, Houston, TX) were added for 30 minutes prior
to EGF (100ng/ml) stimulation for 15 minutes as previously described
[21]. Cells were lysed and examined for kinase activation using standard
western blot procedures.
2.3. Immunoﬂuorescence assay
Cells were cultured in 96-well plates (5,000 cells/well). After 24 h
of plating, treatments were added for 72 h. The media was removed,
cells were washed with PBS and ﬁxed with 4% paraformaldehyde for 10
minutes. The cells were washed and incubated with blocking buﬀer for
1 hour at room temperature. Primary antibodies (𝛼-actinin, 𝛼-tubulin,
ZEB1 and Ki67) were added at a dilution of 1:750 and the plate was incubated at 4°C overnight. The cells were washed with PBS three times at
5-minute intervals. Secondary antibodies (Goat anti-mouse Alexa Flour
488nm and goat anti-Rabbit Alexa Flour 555nm (1:1000, Invitrogen),
counterstained with Hoechst (Fisher) were added for 1 hour at room
temperature. Cells were washed with PBS three times at 5-minute intervals and the pictures were taken using the EVOS microscope (Thermo
Fisher Scientiﬁc, Waltham, MA) at 10X magniﬁcation.
2.4. Migration assay
Cells were cultured in a 12-well plate (150,000 cells/ well). The compounds were added for 48 h and a scratch was made using 10 μl pipette
tip. The underside of the plate was marked to denote the location of
the initial wound. Cells were washed gently with 1x PBS to remove detached cells and debris. Treatments were added in fresh media, images
were taken, and the plate was returned to the incubator for 24 h. The
images were taken after 24 h from the time of scratch and the wound
closure was calculated by the formula: (scratch at 24 h) – (scratch at 0
h) / (scratch at 0 h) X 100.
2.5. Lentivirus treatment
Lentivirus plasmids were a generous gift from Dr. Zhengui Xia (University of Seattle, Washington). Cells were cultured in a 12-well plate
(150,000 cells/ well). The volume of required per well lentivirus (μL)
was calculated as [(# of cells/well x desired multiplicity of infection
(MOI)/viral titer (IU/μL)].. This volume of lentivirus was diluted in fresh
media and 50% of media was replaced with the lentivirus-containing
media. The infection eﬃciency was greater than 60% after 24 hours of
treatment at MOI=1, as calculated by microscopic observation of the
percentage of GFP-positive cells. The cells were infected with lentivirus
at the MOI =1 for 96 h. Immunoﬂuorescence staining and western blotting were performed to examine cell morphology, E-cadherin and ZEB1
protein expression or ERK1/2 and ERK5 activation.

2. Material and methods
2.6. Cell lysis and Western Blotting
2.1. Cell culture
Cells were cultured in a 6-well plate (250,000 cells/well) for 24 h.
After 24 h, the inhibitors were added to the cells for 72 h to examine
kinase activation and MET markers. The cells were lysed in ice-cold 1X
cell lysis buﬀer (Cell Signaling Technology, Danvers, MA) buﬀer and
0.1 M PMSF. The lysates were centrifuged at 10,000 rpm for 10 minutes at 4°C. The supernatant was collected and stored at -80°C until
further analyses. The lysates were denatured using 𝛽-mercaptoethanol.
Bradford (Bio-Rad, Hercules, CA) protein assay was performed to determine the protein concentrations in the lysates. 30 μg of protein was
loaded on 8% SDS-PAGE gels. The gels were transferred to nitrocellulose
membranes. The membranes were incubated in casein blocking buﬀer

MDA-MB-231 and MDA-MB-231 VIM RFP cells (ATCC, Manassas,
VA) were cultured in DMEM: F-12 and BT-549 and MCF-7 (ATCC)
cells were cultured in RPMI media supplemented with 5% FBS (Gibco,
Thermo Fisher Scientiﬁc, Waltham, MA), respectively. TUBcX-4IC
patient-derived primary TNBC cells were generously provided by Burow
lab. TU-BcX-4IC cells were cultured in DMEM:F-12 (1:1) media supplemented with 10% FBS and 1% Pen/Strep. TAMR-MCF-7 cells were cultured in phenol red free RPMI media supplemented with 5% charcoalstripped FBS as previously described [20]. The cells were maintained at
37°C and 5% CO2 as per standard manufacturer’s protocol.
2
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3. Results

at room temperature for 1 h. Primary antibodies ERK5, ERK1/2, ZEB1,
pERK1/2 (phospho-p44/42), p-P90RSK (S380), RSK1/2/3, 𝛼-tubulin,
and E-cadherin (Cell Signaling Technology) were added and the membranes were incubated at 4°C overnight. The membranes were washed in
PBS-0.1% tween solution three times at 10-minute intervals. Secondary
antibodies were added, and the membranes were incubated for 1 h and
washed three times at 10-minute intervals at room temperature. The
membranes were washed with PBS and scanned using an Odyssey (LICR, Lincoln, NE) imager at 700 and 800 nm wavelength. The blots were
quantiﬁed using Image Studio Lite (LI-COR Biosciences).

3.1. ERK1, ERK2, and ERK5 expression correlates with EMT markers and
is associated with poor patient survival in breast cancer
Since the eﬀect of ERK1/2 and ERK5 pathways on EMT is less
well-understood in TNBCs, we ﬁrst used publicly available datasets
from Purrington, K. S. and colleagues [22] to correlate MAPK3 (ERK1),
MAPK1(ERK2), or MAPK7 (ERK5) gene expression with EMT markers CDH1 (E-cadherin), ZEB1, or vimentin in primary, invasive tumors
derived from African-American TNBC patients (Fig. 1). There was a
moderate to strong signiﬁcant correlation between MAPK3, MAPK1,
and MAPK7 with mesenchymal markers ZEB1 and vimentin. Moreover,
we performed Kaplan-Meier survival analysis to examine relation between ERK1/2/5 expression and patient survival in inﬂammatory breast
cancer using publicly available datasets from Bertucci and colleagues
[23] MAPK3, MAPK1, or MAPK7 gene expression was found to be associated with poor patient survival in patients with inﬂammatory breast
cancer (Fig. 2). Overall, these data suggest that ERK1, ERK2, and ERK5
are important therapeutic targets in breast cancer.

2.7. Nuclear/Cytosolic fractionation
Cells were cultured in 6-well plates (500,000 cells/well) for 24 h.
After 24 h, cells were treated with the kinase inhibitors for 72 h. The
nuclear/ cytosolic fractionation was performed using standard manufacturer’s instructions (Cell Biolabs, San Diego, CA). In brief, the medium
was aspirated, and cells were washed with pre-chilled 1X PBS. DTT and
Protease inhibitor cocktail was added to Cytosol Extraction Buﬀer (CEB).
100 μL CEB was added to cells for 10 minutes. Cells were scraped and
collected in 1.5 mL pre-chilled microcentrifuge tubes. Cell lysis buﬀer
was added for 5-15 minutes and the lysates were vortexed for 10 seconds. The lysates were centrifuged at 10,000 rpm for 10 minutes at 4°C.
The supernatant (cytosolic fraction) was collected and stored at -80°C.
The pellet was resuspended in CEB and lysis buﬀer was added for 10
minutes. The suspension was vortexed and centrifuged at 10,000 rpm
for 10 minutes at 4°C. The supernatant was discarded, this step was performed to ensure clean separation. The pellet was resuspended in 40 μL
nuclear extraction buﬀer (NEB) with DTT and protease inhibitors. The
solution was incubated on ice for 30 minutes with occasional vortexing.
The samples were centrifuged at 14,000 rpm for 30 minutes at 4°C. The
supernatant (nuclear fraction) was stored at -80°C.

3.2. Pharmacological inhibition of the ERK1/2 and/or ERK5 pathways
induces MET in TNBC and TAMR cells
MDA-MB-231, BT-549, and TU-BcX-4IC TNBC cells were treated with
increasing concentrations of XMD8-92 and trametinib for 72 hours.
Moreover, the eﬀects of XMD8-92 and trametinib were evaluated on
MET and kinase signaling in tamoxifen-resistant (TAMR) MCF-7 ERpositive breast cancer cells, which have a mesenchymal phenotype.
The generation of TAMR-MCF-7 cells in our lab and evidence of EMT
have been previously reported [20]. Trametinib induced a morphological switch from mesenchymal to epithelial in all the cell lines, while
XMD8-92 only induced this morphological change in MDA-MB-231 cells
(Fig. 3).
In MDA-MB-231 cells, trametinib increased E-cadherin expression
and decreased ZEB-1 expression, markers of epithelial and mesenchymal phenotypes, respectively. XMD8-92 decreased the expression of
ZEB1 but had no eﬀect on E-cadherin expression at low doses, and
decreased E-cadherin expression at the highest dose in MDA-MB-231
cells (Fig. 3A). Treatment with trametinib signiﬁcantly increased Ecadherin and led to a trending decrease in ZEB1 expression in BT-549
cells (Fig. 3B). Trametinib, but not XMD8-92 signiﬁcantly decreased
ZEB1 expression in TU-BcX-4IC cells. XMD8-92 did not alter cell morphology, E-cadherin, or ZEB1 expression in TAMR MCF-7 cells (Fig. 3C).
In order to examine the extent of MET induced by the inhibitors,
we correlated the expression of E-cadherin to ZEB1. Treatment that induced E-cadherin expression by greater than 3-fold and decreased ZEB1
by greater than 0.3-fold was determined to induce a full MET switch
whereas treatment that either induced 3-fold increase in E-cadherin expression or 0.3-fold was determined to induce a partial MET. Trametinib
induced a full MET in MDA-MB-231 and TAMR MCF-7 cells at low and
high doses whereas it induced a partial MET in BT-549 cells as noted
by a signiﬁcant increase in E-cadherin expression (Supplemental Figure
1). Therefore, we correlated WT-MCF-7 epithelial cells were included
as a control to study EMT. We observed that treatment with XMD8-92
or trametinib did not alter cell morphology or E-cadherin expression in
WT-MCF-7 cells (Supplemental ﬁgure 2A, B).

2.8. Spheroid assay
Cells were cultured in a 96-well plate (5000 cells/ well). After 24
h of plating, the spheroids were treated with diﬀerent concentrations
of the MAPK and/or AKT inhibitors and allowed to grow for 7 days.
The pictures of spheroids were taken at the time of treatment and after 7 days of treatment. At the experimental endpoint, 10 μL Reliablue
reagent (ATCC) was added to each well and the plate was returned to
the incubator for 3 h. The ﬂuorescence was measured at ex570/ em590
on a Synergy microplate reader (Biotek, Winooski, VT).
2.9. MTT cell viability assay
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was performed to determine cell viability. Cells were
seeded at a density of 5,000 per well in 96-well plates containing 90 𝜇l
of full media for 24 h and then treated with increasing concentrations
of trametinib and/or XMD8-92 for 72 h. 10 𝜇L of MTT (Acros, Cat.
No. 298-93-1) solution (5 mg/ml in phosphate-buﬀered saline, PBS)
was added to each well and the plate was incubated at 37°C for 3 h.
After removal of the MTT solution from each well, 100 𝜇l of DMSO was
added to the wells for 10 min under agitation to dissolve the formazan
crystals. Absorbance was measured at a wavelength of 570 nm.
2.10. Statistical analyses
Genomics data were analyzed using R2: Genomics analysis and visualization plaltform (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi).
One-way or two-way analysis of variance (ANOVA) with Bonferroni
post-hoc correction was applied to determine statistical signiﬁcance
across diﬀerent concentrations of individual drugs compared to the control (DMSO or GFP) or to the individual drug where combination treatment was performed. GraphPad Prism version 7.03 for Windows (GraphPad Software La Jolla, California) was used for statistical analyses.

3.3. Trametinib and XMD8-92 diﬀerentially modulate ERK5 activation in
breast cancer
The eﬀects of XMD8-92 and trametinib were evaluated on ERK1/2,
ERK5, and RSK activation in MDA-MB-231, BT-549, TU-BcX-4IC and
TAMR MCF-7 cells at short time points (Supplemental ﬁgure 3) and after 72 hours of treatment (Fig. 4). At 72 hours, XMD8-92 decreased
activation of RSK, a downstream target of ERK5 in MDA-MB-231 and
3
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Fig. 1. Correlation of ERK1, ERK2, or ERK5 with EMT markers in tumors derived from TNBC patients. Gene correlation between (A) MAPK3(ERK1),
(B) MAPK1(ERK2), or (C) MAPK7 (ERK5) and EMT markers CDH1, ZEB1, or VIM was plotted using R2: Genomics analysis and visualization platform
(https://hgserver1.amc.nl/cgi-bin/r2/main.cgi). Datasets were exported from Tumor Breast (triple negative) - Purrington - 226 - rma_sketch - hugene21t.

TAMR MCF-7 cells but not in BT-549 and TU-BcX-4IC cells. As expected,
trametinib signiﬁcantly decreased ERK1/2 and/or RSK phosphorylation
in MDA-MB-231, BT-549, TU-BcX-4IC and TAMR MCF-7 cells (Fig. 4).
p-P90RSK protein expression was undetected in WT-MCF-7 cells (Supplemental ﬁgure 2C).
Surprisingly, XMD8-92 did not decrease ERK5 activation at 72 hours
in any model (Fig. 4). Therefore, ERK5 activation may be an early event
that leads to alterations in cell signaling downstream at later time points.
To examine this, cells were serum starved for 18-24 hours, treated with
an inhibitor for 30 minutes, and then with epidermal growth factor
(EGF) for 15 minutes. XMD8-92 decreased EGF-mediated ERK5 activation in MDA-MB-231 and TAMR-MCF-7 cells, but not in BT-549 or TUBcX-4IC cells (Supplemental ﬁgure 3) which is consistent with the eﬀects
of XMD8-92 on RSK phosphorylation at 72 hours. Interestingly, XMD892 activated ERK1/2 in MDA-MB-231 cells compared to DMSO+EGF
treatment control at short time points. This may be due a compensatory
upregulation of ERK1/2 activity due to inhibition of ERK5 activation.
Trametinib signiﬁcantly inhibited ERK1/2 activation at 72 hours in
all cell types studied (Fig. 4). Interestingly, trametinib did not signiﬁ-

cantly decrease RSK phosphorylation in BT-549 cells (Fig. 4B). This may
be because these cells are inherently dependent on alternative signaling
pathways for RSK activation or EMT. Moreover, it is possible that AKT
activation may mediate resistance to kinase inhibition in these cells,
since the crosstalk between the MAPK and AKT pathways has been noted
previously [24]. These data may explain why trametinib only partially
induced MET in these cells. Trametinib also increased ERK5 phosphorylation in TU-BcX-4IC cells at 72 hours (Fig. 4C). Again, this may be a
compensatory upregulation of ERK5 and/or indicate that ERK5 plays a
lesser role in the EMT in these cells.
Trametinib signiﬁcantly decreased ERK1/2, ERK5, and RSK phosphorylation in response to EGF stimulation in MDA-MB-231 cells in a
dose-dependent manner at short time points (Supplemental ﬁgure 3A).
However, trametinib signiﬁcantly decreased ERK1/2 and RSK phosphorylation, but not ERK5 phosphorylation, in BT-549, TU-BcX-4IC, and
TAMR MCF-7 cells (Supplemental ﬁgure 3B-D). These data indicate that
trametinib may be a dual inhibitor of ERK1/2 and ERK5 pathways in
MDA-MB-231 cells, but not in BT-549, TU-BcX-4IC, and TAMR MCF-7
cells.

4
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Fig. 2. MAPK3, MAPK1, and MAPK7 expression correlates with poor patient survival in breast cancer. Disease free survival was analyzed using R2: Genomics
analysis and visualization platform (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi). Datasets were exported from Tumor Breast (MDC) Bertucci - 266 - MAS5.0 u133p2.

Fig. 3. ERK1/2 and ERK5 pathway inhibition induces MET in TNBC and TAMR MCF-7 cells. Cells were treated with XMD8-92 and trametinib at increasing
concentrations for 72 hours. Cell morphology (20X magniﬁcation) and western blot analysis of EMT markers E-cadherin and ZEB1 in (A) MDA-MB-231 cells. (B)
BT-549 cells (C) TU-BcX-4IC and (D) TAMR MCF-7 cells. Data represent the ± SEM of three diﬀerent experiments for each inhibitor compared to DMSO control.
∗
p<0.05; ∗ ∗ p<0.01; ∗ ∗ ∗ p<0.001; ∗ ∗ ∗ ∗ p<0.0001 vs DMSO control group determined by one-way ANOVA with the Bonferroni post hoc test.

3.4. Eﬀects of XMD8-92 and trametinib on cell migration and proliferation
in breast cancer

are similar to the morphology pictures shown in Fig. 3 with Ki67 added
as the proliferation marker.

EMT is known to promote cell migration [25-26]. XMD8-92 decreased cell migration in MDA-MB-231 and TAMR-MCF-7 cells at 10
𝜇M concentration (Fig. 5A-D). Trametinib signiﬁcantly decreased cell
migration in TNBC and TAMR breast cancer cells (Fig. 5A-D). XMD8-92
produced a signiﬁcant decrease in proliferative fraction of MDA-MB231, TU-BcX-4IC, and TAMR-MCF-7 cells (Fig. 5E, G-H) but not in BT549 cells (Fig. 5F). The immunostaining pictures for cell proliferation

3.5. Trametinib decreases nuclear ERK5 in MDA-MB-231, but not in
BT-549 cells
ERK5 has a large C-terminal domain, which can facilitate its nuclear
localization in response to growth factors or via autophosphorylation
[27]. The location speciﬁc roles of ERK5 remain largely understudied.
To understand diﬀerences in the signaling pathway across TNBC sub5
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Fig. 4. Western blot analysis of ERK5, ERK1/2, and RSK activation in TNBC cells. (A) MDA-MB-231, (B) BT-549, (C) TU-BcX-4IC, and (D) TAMR MCF-7 cells.
Data represent the ± SEM of three diﬀerent experiments for each inhibitor compared to DMSO control. ∗ p<0.05; ∗ ∗ p<0.01; ∗ ∗ ∗ p<0.001; ∗ ∗ ∗ ∗ p<0.0001 vs DMSO
control group determined by one-way ANOVA with the Bonferroni post hoc test.

types, we selected two models: MDA-MB-231 driven by mutations in
RAF, leading to activation of the MEK-ERK pathway activation and BT549 cells driven by loss of PTEN and subsequent increase in the PI3KAKT pathway activation. MDA-MB-231 and BT-549 cells were treated
with DMSO, 1 𝜇M XMD, and 0.1 𝜇M trametinib for 72 hours. ERK5 was
found to be basally active and localized in the nucleus as well as the
cytosol of MDA-MB-231 and BT-549 TNBC cells (Fig. 6). ERK1/2 was
mainly localized in the cytosol of the TNBC cells and its activation or
expression was not altered with XMD8-92. Trametinib did not decrease
ERK5 activation but decreased the total expression in the nucleus as
well as the cytosol of MDA-MB-231 cells, while it only decreased ERK5
activation in the cytosol of BT-549 cells (Fig. 6A, B). As expected, trametinib but not XMD8-92 signiﬁcantly decreased ERK1/2 activation in
the cytosol in MDA-MB-231 and BT-549 cells. Total ERK1/2 expression
was not altered with either treatment in the cytosol of either cell line.
We wanted to further evaluate the eﬀects of dual ERK1/2 and ERK5
pathway activation or inhibition on EMT using lentivirus.

cated for 96 hours. The morphology of infected cells was assessed via
immunostaining for the cytoskeletal protein 𝛼-actinin (Fig. 7A). Cells
that were infected with dnMEK1 and dnMEK5 alone or in combination
displayed a phenotypic shift from a mesenchymal to epithelial. caMEK1,
caMEK5, and caMEK5+caMEK1 treatments increased the mesenchymalization of MDA-MB-231 and BT-549 cells (Fig. 7A, C). caMEK5 and
caMEK1+caMEK5 signiﬁcantly increased ERK5 activation in MDA-MB231 cells (Fig. 7B). There were no signiﬁcant decreases or increases in
ERK1/2 phosphorylation in MDA-MB-231 cells. dnMEK1 and dnMEK5
did not signiﬁcantly decrease ERK5 or ERK1/2 in BT-549 cells; however,
caMEK1 and caMEK1+caMEK5 groups signiﬁcantly increased ERK1/2
activation in BT-549, but not MDA-MB-231 cells (Fig. 7D).
3.7. MEK1 and MEK5 pathways regulate ZEB1 expression in TNBC cells
Next, we wanted to examine cell-speciﬁc responses to MEK1/2 and
MEK5 pathway inhibition and activation on EMT. Therefore, MDA-MB231 and BT-549 cells infected with dnMEK1, dnMEK5, caMEK1, and
caMEK5 lentivirus vectors alone and in combination were assessed for
decreases and increases in ZEB1 expression by immunoﬂuorescence.
MDA-MB-231 cells that were infected with dnMEK1, dnMEK5, and
dnMEK1+dnMEK5 vectors (GFP+ cells) had an attenuated ZEB1 expression (Fig. 8A). While cells infected with caMEK1, caMEK5, and
caMEK1+caMEK5 groups had a more pronounced mesenchymal morphology compared to GFP control, there were no increases in ZEB1
expression (Fig. 8A). BT-549 cells that were infected with dnMEK1,
dnMEK5, and dnMEK1+dnMEK5 groups appeared epithelial but had

3.6. Diverse and converging roles of MEK1 and MEK5 on EMT and kinase
activation in TNBC cells
To further examine the roles of the ERK1/2 and ERK5 pathways
on MET and kinase activation, MDA-MB-231 and BT-549 cells were
treated with dominant negative (dn) and constitutively active (ca)
lentivirus vectors of MEK1 and MEK5 (generous gift from Dr. Zhengui Xia). The cells were transiently co-infected with GFP-tagged dnMEK1, dnMEK5, caMEK1, and/or caMEK5 lentivirus vectors as indi6
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Fig. 5. XMD8-92 and trametinib diﬀerentially decrease cell migration and proliferation in diverse breast cancer subtypes. (A) MDA-MB-231, (B) BT-549
cells, (C) TU-BcX-4IC, and (D) TAMR MCF-7 cells were treated with the kinase inhibitors and scratches were made after 48 hours of treatment. Cells were imaged at
the time of scratch (0 h) and after 24 hours from the time of scratch (72 h) (20X magniﬁcation). Cell migration was measured as a percentage of DMSO control group.
(E) MDA-MB-231, (F) BT-549, (G) TU-BcX-4IC and (H) TAMR MCF-7 cells were treated with XMD8-92 or trametinib for 72 hours (20X magniﬁcation). Proliferative
fraction was evaluated as the number of Ki67 positive cells divided by the number of Hoechst positive cells. Data represent the ± SEM of three diﬀerent experiments.
∗
p<0.05; ∗ ∗ p<0.01; ∗ ∗ ∗ p<0.001; ∗ ∗ ∗ ∗ p<0.0001 vs. DMSO control group determined by one-way ANOVA with the Bonferroni post hoc test.

Fig. 6. Eﬀect of XMD8-92 and trametinib on ERK5 and ERK1/2 activation in the nucleus and cytoplasm. (A) MDA-MB-231 nuclear fraction (B) MDA-MB-231
cytosolic fraction (C) BT-549 nuclear fraction (D) BT-549 cytosolic fraction (72 h). ∗ p<0.05; ∗ ∗ ∗ p<0.001 vs control group determined by one-way ANOVA with the
Bonferroni post hoc test.
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Fig. 7. MEK1 and MEK5 activation mediates EMT in TNBC cells. (A, B) MDA-MB-231 and (C, D) BT-549 cells were treated with dnMEK5, dnMEK1, caMEK5,
and caMEK1 alone and in combination as represented in the ﬁgure. The cells were incubated for 96 hours. Immunoﬂuorescence staining for 𝛼-actinin was performed
to assess the morphology (40X magniﬁcation). The eﬀect on ERK1/2 and ERK5 activation was evaluated. ∗ p<0.05; ∗ ∗ p<0.01 vs GFP control group determined by
one-way ANOVA with the Bonferroni post hoc test.

no reduction in ZEB1 expression (Fig. 8B). caMEK1, caMEK5, and
caMEK1+caMEK5-infected cells had a more pronounced mesenchymal
morphology and showed an increase in ZEB1 expression (Fig. 8B).
MDA-MB-231 and BT-549 cells were treated with 0.1 𝜇M trametinib in the presence of GFP or caMEK5 lentivirus to examine the effects on cell morphology, E-cadherin, and ZEB1 expression. MDA-MB231 cells treated with trametinib, which transitioned to an epithelial
phenotype, had a reduction in ZEB1 expression. The reduction in ZEB1
was rescued in cells that were infected with caMEK5 as determined by
immunoﬂuorescence (Supplemental ﬁgure 4). While caMEK5 did not
inhibit trametinib-mediated increases in E-cadherin expression (Supplemental Figure 5), it did reduce trametinib-mediated decrease in ZEB1 expression as determined by western blotting in MDA-MB-231 cells (Supplemental Figure 5A-B) but not in BT-549 cells (Supplemental Figure
5C-D). Putative signaling mechanisms driving EMT in TNBC are outlined (Supplemental Figure 5D, H).

3.8. MEK1 and/or MEK5 activation reduces the ability of trametinib to
decrease vimentin expression in MDA-MB-231 VIM RFP 2D and spheroid
cultures
The eﬀect of dual ERK1/2 and ERK5 pathway inhibition on MET
was found to be most promising in MDA-MB-231 cells. Therefore, to
strengthen the functional contribution of inhibiting the ERK1/2 and
ERK5 pathways in MET, MDA-MB-231 VIM RFP cells, a new model for
MET research, were infected with caMEK1 and/or caMEK5 in the presence of DMSO, trametinib, or XMD8-92. These cells have been transformed to constitutively express vimentin, a mesenchymal marker via
CRISPR-knock-in system and serve as a good model to study MET. MET
was examined via observing vimentin expression in 2D and spheroid
cultures as well as spheroid viability after treatment with constitutively
active MEK isoforms in the presence or absence of MAPK inhibitors.
Treatment with caMEK1, caMEK5, and caMEK1+caMEK5 increased vi-
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Fig. 8. MEK1 and MEK5 activation mediates ZEB1 expression in TNBC cells. (A) MDA-MB-231 and (B) BT-549 cells were treated with dnMEK5, dnMEK1,
caMEK5, and caMEK1 alone and in combination as represented in the ﬁgure. The cells were incubated for 96 hours. Immunoﬂuorescence staining for ZEB1 was
performed (40X magniﬁcation).

mentin expression (Fig. 9A). While treatment with XMD8-92 alone did
not reduce vimentin expression, treatment with trametinib moderately
decreased vimentin expression, speciﬁcally in cells that underwent a
MET as determined by examining morphology of GFP+ cells via microscopy (Fig. 9A). Treatment with constitutively active MEK1, MEK5,
and MEK1+caMEK5 reduced the ability of trametinib to decrease vimentin expression.
In spheroid culture, trametinib but not XMD8-92 reduced expression
of vimentin at 96 hours, which was rescued in the presence of caMEK1,
caMEK5, and caMEK1+caMEK5 groups (Fig. 9B). Spheroid viability was
assessed after 7 days of treatment (Fig. 9C). There was no baseline difference in spheroid viability after treatment with caMEK1, caMEK5, or
caMEK1+caMEK5 groups. This may indicate that the spheroid-forming
ability of MDA-MB-231 VIM RFP cells is at its maximum and cannot
be increased further. XMD8-92 signiﬁcantly decreased spheroid viability at 1 and 10 μM concentrations. As expected, the reduction in
spheroid viability at 1μM XMD8-92 concentration was rescued by cotreatment with caMEK5 or caMEK1+caMEK5 groups. The rescue eﬀect
by caMEK5 or caMEK1+caMEK5 groups was reversed in the presence of
higher XMD8-92 concentration (10μM). While trametinib signiﬁcantly
decreased spheroid viability at 0.1μM concentration, these eﬀects were
not reversed in the presence of caMEK1, caMEK5, and caMEK1+caMEK5
groups (Fig. 9C). Pictures of vimentin-expressing spheroids at day 0, day
7, and evidence of lentivirus infection measured by examining GFP expression in spheroids are included in Supplemental Fig. 6.

tal Fig. 7). However, in contrast to TNBC cells, Tra+XMD combination
was eﬀective in producing a synergistic inhibition of spheroid viability
in TAMR MCF-7 cells (Fig. 10 and Supplemental Fig. 7). XMD8-92 did
not signiﬁcantly decrease spheroid viability in BT-549, TU-BcX-4IC, and
TAMR-MCF-7 cells (Fig. 10B-D). The reduction in spheroid viability in
response to trametinib was greater in MDA-MB-231 cells (~90%) compared to BT-549 (~40%), TU-BcX-4IC (~35%) or TAMR-MCF-7 cells
(~40%). Moreover, the spheroids were treated with novel MAPK inhibitors SC-1-151 (dual MEK1/2 and MEK5 inhibitor) and SC-1-181
(MEK5 inhibitor) in combination with ipatasertib, an AKT inhibitor.
Ipatasertib did not decrease spheroid viability but its eﬀect was potentiated by MEK inhibitors in MDA-MB-231 and TAMR MCF-7 cells
(Fig. 10A, C). Ipatasertib alone and in combination with MEK inhibitors
synergistically decreased spheroid formation in BT-549 and TU-BcX-4IC
cells (Fig. 10B, D).
4. Discussion
Mesenchymal cancer cells are migratory and invasive, leading to
metastases. There are currently no eﬀective treatments for metastases.
Interestingly, activation of the ERK1/2 and ERK5 signaling pathways
leads to an epithelial to mesenchymal transition (EMT) and poor patient
survival, in several cancers, including TNBC and endocrine-resistant
breast cancers [11–13, 28–33]. Genomics data from our research indicates that MAPK3 and MAPK7 gene expression signiﬁcantly correlated with mesenchymal marker VIM or ZEB1 but not with epithelial marker CDH1 (Fig. 1A and C). MAPK1 positively correlated with
mesenchymal markers VIM and ZEB1 and epithelial marker CDH1 (Ecadherin), indicating that MAPK1 may mediate an intermediate epithelial/mesenchymal state where both epithelial and mesenchymal markers
are co-expressed (Fig. 1B). These data suggest that ERK1/2 and ERK5
are relevant targets for treatment of TNBC. However, the relative roles
of these pathways in inducing the MET in these cancers is unknown.
Understanding of the tumor biology and response to therapy is further
complicated due to crosstalk between the ERK1/2 and ERK5 pathways
and diﬀerent functions of ERK5 in the nucleus versus the cytosol. To

3.9. Eﬀect of dual ERK1/2 and ERK5 pathway inhibition on spheroid
formation and ipatasertib sensitivity in breast cancer
EMT is known to promote anchorage-independent growth [25,26].
We found that trametinib alone signiﬁcantly decreased spheroid viability and/or cell viability in all breast cancer models and its eﬀects
were most pronounced in MDA-MB-231 cells (Fig. 10A-D). While XMD
only decreased spheroid viability in MDA-MB-231 cells, Tra+XMD combination did not produce a greater eﬀect on spheroid or cell viability
compared to individual drugs in TNBC cells (Fig. 10 and Supplemen9
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Fig. 9. MEK1 and/or MEK5 activation reduces the ability of XMD8-92 or trametinib to decrease spheroid viability or vimentin expression in MDA-MB-231
VIM RFP model. (A) MDA-MB-231 VIM RFP cells were treated with constitutively active MEK1, MEK5, and MEK1+MEK5 in the presence of DMSO, XMD8-92,
or trametinib for 72 hours. The cells were ﬁxed and stained with Hoechst. Images of Vimentin-, GFP-, and Hoechst-expressing cells were captured under 40X
magniﬁcation using EVOS microscope (n=3, most representative image shown). (B) MDA-MB-231 VIM RFP cells were treated with constitutively active MEK1,
MEK5, and MEK1+MEK5 in the presence of DMSO, XMD8-92, or trametinib for 96 hours. Images of spheroids under transmitted light and RFP channel were
captured under 4X magniﬁcation using EVOS microscope (n=3, most representative image shown). (C) Spheroid viability was assessed after 7 days of treatment
with the same groups. Data indicate ± SEM of experiments run in triplicate. ∗ ∗ ∗ p<0.001; ∗ ∗ ∗ ∗ p<0.0001 vs DMSO control group, #p<0.05; vs individual drug+GFP
determined by two-way ANOVA with the Bonferroni post hoc test.

our knowledge, this is the ﬁrst study to examine the independent and
overlapping roles of the ERK1/2 and ERK5 signaling cascades on MET,
nuclear localization of ERK5, cell migration, proliferation, and spheroid
formation in breast cancer.
In the current study, trametinib, a clinically relevant MEK1/2 inhibitor, and XMD8-92, an ERK5 inhibitor, induced a MET in MDA-MB231 TNBC cells as shown by morphological characteristics, increased
expression of E-cadherin, and/or decrease in ZEB1 (Fig. 3A). In BT-549,
TU-BcX-4IC, and TAMR MCF-7 cells, treatment with trametinib, but not
XMD8-92, resulted in an epithelial-like morphology (Fig. 3B-D). However, the morphological changes induced by trametinib in BT-549 cells
were less pronounced than those in MDA-MB-231 cells, probably because trametinib inhibited ZEB1 in 231 cells, but not in BT-549 cells.
The morphological changes induced by trametinib in the 231 cells were
more pronounced than those induced by XMD8-92. This may be because trametinib increased E-cadherin expression and decreased ZEB1
expression, while XMD8-92 only reduced ZEB1 expression in 231 cells.
Overall, these data suggest that inhibition of the ERK1/2 pathway alone
is suﬃcient to induce a MET in BT-549, TU-BcX-4IC, and TAMR MCF7 cells. Additionally, as trametinib consistently increased E-cadherin in
TNBC and TAMR breast cancer models, E-cadherin may be used as a
potential biomarker to predict MET induced by trametinib treatment in
metastatic cancers. The inhibitors that induced a partial MET, as determined by ZEB1 and E-cadherin correlation, would have to be combined
with additional EMT suppressors in future since a partial MET state is a
predictor of metastases and poor patient survival [34,35].
Consistent with the eﬀect on MET, trametinib decreased cell migration in TNBC and TAMR MCF-7 cells, suggesting that ERK1/2 inhibition
is suﬃcient to decrease cell migration in these cells. At 10 𝜇M concentra-

tion, XMD8-92 decreased cell migration only in MDA-MB-231 cells. This
observation is consistent with reduction in ZEB1 and induction of MET
following treatment with XMD8-92 in MDA-MB-231 cells. ERK1/2 and
ERK5 activation are known to mediate cell proliferation by mediating
G1-S transition during the cell cycle via distinct eﬀects on cyclinD1 expression and activation [36]. Trametinib decreased cell proliferation by
80% in TAMR MCF-7 cells. However, in MDA-MB-231 cells, trametinib
only decreased cell proliferation by ~50%. Although not statistically
signiﬁcant, this decrease in cell proliferation by trametinib may be biologically relevant. Moreover, MEK1/2 inhibition decreased colony formation by 20% and ERK5 inhibition did not decrease colony formation
in MDA-MB-231 cells (data not shown). The eﬀect of XMD8-92 on cell
proliferation was evident only at the highest dose (10 𝜇M) in MDA-MB231 and TAMR MCF-7 cells. We have previously shown that eﬀects of a
high XMD8-92 dose could be recapitulated by the addition of AX15836
(ERK5 inhibitor) and CPI203 (BRD4 inhibitor) [24]. Therefore, at high
doses, in addition to ERK5 inhibition, XMD8-92 may have oﬀ-target effects including inhibition of bromodomain (BRD)4 [37]. Trametinib or
XMD8-92 did not decrease cell proliferation in BT-549 cells, which may
indicate that alternative pathways mediate cell proliferation in these
cells. As indicated above, BT-549 cells are PTEN mutant cells and may
rely more on the AKT pathway for survival and proliferation.
XMD8-92 is a well-known ERK5 inhibitor [38]. We have seen previously that XMD8-92 inhibits ERK5 at as low as 3 or 5 𝜇M concentration [24]. In this study, we have data that show that ERK5 activation
by EGF is inhibited signiﬁcantly in the presence of 1 𝜇M XMD8-92 in
MDA-MB-231 and TAMR-MCF-7 cells. Therefore, the lack of eﬀect of
XMD8-92 on ERK5 in BT-549 and TU-BcX-4IC cells may be due to compensatory increase in the AKT pathway or paradoxical activation and
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Fig. 10. Eﬀect of ERK1/2 and ERK5 inhibition alone and together on spheroid viability and ipatasertib sensitivity in diverse breast cancer subtypes. The
spheroids were treated with increasing concentrations of XMD8-92 and/or trametinib for 7 days. Pictures of spheroids were obtained before treatment and 7 days
after treatment (4X magniﬁcation) (A) MDA-MB-231, (B) BT-549, and (C) TU-BcX-4IC, and (D) TAMR MCF-7 cells. Eﬀect of SC-1-151 and SC-1-181 alone and in
combination with ipatasertib on spheroid viability in (E) MDA-MB-231, (F) BT-549, (G) TU-BcX-4IC and (H) TAMR MCF-7 cells. Spheroid viability was assessed
on day 7 after treatment. Data indicate ± SEM of experiments run in triplicate ∗ p<0.05; ∗ ∗ p<0.01; ∗ ∗ ∗ p<0.001; ∗ ∗ ∗ ∗ p<0.0001 vs DMSO control group, ##p<0.01;
###p<0.001; ####p<0.0001 vs individual drug determined by one-way ANOVA with the Bonferroni post hoc test.

nuclear translocation of ERK5. Eﬀect of trametinib was also less pronounced on RSK inhibition in these cells. It is also possible that inherently constitutively active AKT in BT-549 cells may be causing resistance
to MAPK inhibitors. Above 10 𝜇M concentration, XMD8-92 has toxic
eﬀects on cells as well as oﬀ-target eﬀect on BRD4 and hence would
confound data interpretation.
We observed that MDA-MB-231 cells were the most responsive to the
eﬀects of XMD8-92 and trametinib on MET, whereas BT-549 cells were
the least responsive, which led us to characterize diﬀerences in cellular
signaling between the two TNBC models. We wanted to characterize
dual role of MEK1/2 and MEK5 pathways on EMT, nuclear localization
of ERK5, and their relation to the PI3K-AKT pathway. We ﬁrst examined
the eﬀects of trametinib and XMD on nuclear localization of ERK5. To
further explore our hypothesis that inhibition of both the ERK1/2 and
ERK5 pathways are necessary to induce the MET in TNBC, MDA-MB231 and BT-549 cells were infected with dominant negative (dn) and
constitutive active (ca) MEK1 and/or MEK5. We believe that this is the
ﬁrst study to examine nuclear localization of ERK5 in TNBC.
We found that the ERK5 inhibitor did not decrease nuclear ERK5
activation or total expression. This observation is consistent with a recent study, which has shown that ERK5 inhibitors that target the kinase
domain were shown to activate the transcriptional activation domain
(TAD) of ERK5, resulting in the nuclear localization and increased transcriptional activity of ERK5 [39]. This may explain why our data with
respect to the eﬀect of ERK5 inhibition on E-cadherin conﬂicts with studies that have shown that inhibition of ERK5 via knockdown or knockout enhances E-cadherin expression in several cancer models [40,41].
Since trametinib decreased nuclear ERK5, ERK1/2 activation may be
a putative mechanism for the translocation of ERK5 into the nucleus
in MDA-MB-231 cells. ERK1/2 has been shown previously to promote
ERK5 translocation to the nucleus in response to growth factor stimulation [42]. However, constitutively active RAF may be responsible for

constitutive ERK1/2 activation and subsequent translocation of ERK5 in
the nucleus of MDA-MB-231 cells under unstimulated condition. We are
currently investigating mechanisms for ERK5 nuclear translocation in
BT-549 cells. These ﬁndings were further supported by Fig. 7B, where
constitutively active MEK1 and MEK5 lentivirus vectors signiﬁcantly increased ERK5 activation in MDA-MB-231 cells, but not in BT-549 cells.
Although phenotypic shifts were noted following infection of the ca
or dn MEK, the morphological transitions were more pronounced when
both pathways were activated or inhibited in MDA-MB-231 and BT-549
cells. This was supported by decrease in ZEB1 expression in MDA-MB231 cells following dnMEK1 and/or MEK5 infection and increase in
ZEB1 expression in BT-549 cells following caMEK1 and/or MEK5 infection (Fig. 8). It is possible that ZEB1 expression is maximum in MDAMB-231 cells and could not be induced further. The more pronounced
mesenchymal morphology following caMEK5 and caMEK1+caMEK5 infection may be a result of increase in vimentin expression (Fig. 7) or
ERK5 activation (Fig. 7B) and its association with the actin cytoskeleton as previously described [18]. Moreover, ERK5 activation increased
more signiﬁcantly in caMEK1 + caMEK5 group vs GFP than caMEK5
group vs GFP (Fig. 7B), indicating that ERK5 may be activated by both
MEK1 and MEK5 signaling. This observation supports the data that show
that trametinib, a known MEK1/2 inhibitor, decreased ERK5 activation
in MDA-MB-231 cells. We hypothesize that the eﬀect of trametinib on
ERK5 inhibition was mediated via MEK1/2 inhibition and not by direct binding of trametinib to MEK5 or ERK5. Since ERK1/2 and ERK5
share 50% sequence homology at the N-terminal domain, it is possible
that MEK1/2 may phosphorylate ERK5 by direct binding. It is also possible that ERK1/2 may phosphorylate ERK5 at its C-terminal by direct
interaction, as reported previously [42]. These data further support the
conclusion that inhibition or activation of both pathways is necessary
for the MET or EMT, respectively. These data, together with the eﬀect
of trametinib and XMD8-92 on morphology, suggest that inhibition of
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both the ERK1/2 and ERK5 pathways is necessary to induce a full MET
in TNBC cells.
Reduction in trametinib-mediated decrease in ZEB1 expression in
the presence of caMEK5 suggests that trametinib mediates its eﬀect on
MET via dual ERK1/2 and ERK5 inhibition. However, the trametinibmediated increase in E-cadherin expression was not decreased by
caMEK5, which may indicate that trametinib induces E-cadherin expression via ERK1/2 inhibition alone and not ERK5 inhibition (Supplemental Fig. 5). This observation further supports the data that suggest there
is no change in E-cadherin expression following XMD8-92 treatment
in MDA-MB-231 cells. While trametinib caused an overall decrease in
ZEB1 expression in BT-549 cells with an epithelial morphology, caMEK5
did not decrease its ability to induce MET as determined by examining
cell morphology, E-cadherin protein expression by western blotting, and
ZEB1 expression via western blotting and immunoﬂuorescence. This further supports that ERK1/2 inhibition but not ERK5 inhibition induces
MET in BT-549 cells. The role of total ERK5 expression in modulating
EMT in BT-549 cells needs to be further evaluated. We also observed
that there was an overall reduction in ZEB1 expression in cells with an
epithelial morphology following treatment with trametinib in both the
TNBC cell lines and there was no cell population that had a complete
loss of ZEB1. Such ﬁne-tuning could be advantageous to avoid catastrophic side eﬀects on healthy mesenchymal cells in the body, which
depend on ZEB1 for their normal function.
The functional contribution of ERK1/2 and ERK5 pathways to vimentin expression in 2D cultures and spheroids was evaluated in MDAMB-231 cells. Trametinib moderately decreased vimentin expression, in
MDA-MB-231 VIM RFP cells in 2D culture (Fig. 9A), but completely
inhibited vimentin expression in spheroid culture (Fig. 9B), indicating
that treatment with trametinib may be speciﬁcally important in targeting mesenchymal and anoikis-resistant cells. Moreover, trametinibmediated decrease in spheroid viability was not rescued by caMEK1,
caMEK5, and caMEK1+caMEK5 groups at 7 day (Fig. 9C). This indicates that the reduction in vimentin expression in spheroids was not
due to a decrease in spheroid viability. Since these eﬀects of trametinib were partially reversed by co-treatment with constitutively active
MEK1 and/or MEK5, ERK5, in addition to ERK1/2 may be co-regulated
by the MEK1/2 pathway in MDA-MB-231 cells. XMD8-92 signiﬁcantly
decreased the spheroid viability at 1μM concentration, which was rescued by caMEK5 and caMEK1+caMEK5 groups indicating that ERK5 has
a crucial role in regulating the survival of anoikis-resistant spheroids
(Fig. 9C). While ERK1/2 activation has a greater role in regulating
the EMT in spheroids, ERK5 activation regulates the survival of these
anoikis-resistant spheroids.
As previously described, some single-agent inhibitors of MAPK pathway(s) led to an intermediate E/M state, which may be a predictor
of metastases and poor prognosis. Therefore, combination strategy for
MAPK inhibitors needs to be developed. We examined the eﬀect of dual
ERK1/2 and ERK5 pathway inhibition on spheroid viability, an assay
representative of EMT. MAPK gene alterations, including ESR1 overampliﬁcation is common in endocrine-resistant breast cancer [43]. This
explains why Tra and XMD combination produced greater inhibition
of spheroid and cell viability compared to either drug alone in TAMR
MCF-7 cells (Fig. 10 and Supplemental ﬁgure 7D).
As crosstalk between the ERK and AKT signaling pathways has been
noted in TNBC,[24] the AKT pathway may be mediating the resistance to
MAPK inhibitors in TNBC. Therefore, the eﬀect of MAPK pathway inhibition in combination with AKT inhibition was evaluated on spheroid viability in TNBC and TAMR MCF-7 cells. We have previously shown that
a novel, dual inhibitor (SC-1-151/compound 1) of MEK1/2 and MEK5,
the upstream kinases of ERK1/2 and ERK5, respectively, was eﬀective in
inducing an mesenchymal to epithelial transition (MET) in triple negative and TAMR breast cancer [21,20]. SC-1-151-like eﬀects on spheroid
viability were recapitulated by Tra+XMD combination treatment in diverse breast cancer subtypes (Fig. 10). Consistent with the eﬀects on
MET, trametinib decreased spheroid formation in MDA-MB-231 cells to

a greater extent compared to BT-549 or TAMR MCF-7 cells. This diﬀerence may be because trametinib, like SC-1-151, inhibits both ERK1/2
and ERK5 activation by EGF in MDA-MB-231 cells, but only inhibits the
ERK1/2 activation in BT-549, TU-BcX-4IC, and TAMR MCF-7 cells. We
found that dual ERK1/2 and ERK5 inhibition was suﬃcient to decrease
spheroid formation in MDA-MB-231 and TAMR-MCF-7 cells whereas additional inhibition of AKT was necessary further inhibit spheroid formation in BT-549 and TU-BcX-4IC cells. The current study is the ﬁrst to examine the distinct and overlapping roles of the ERK1/2 and ERK5 pathways on breast cancer MET and their relation to the AKT signaling with
respect to EMT. Overall, the data from our research validates ERK1/2
and ERK5 as important therapeutic targets not only in triple-negative
breast cancer but also in other aggressive forms of breast cancers such
as inﬂammatory or tamoxifen-resistant breast cancer.
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